A global biopharmaceutical company transforming access to healthcare through affordable innovation — reaching patients everywhere with lifesaving therapies.
Despite a complex geopolitical environment, Biocon delivered margin expansion and disciplined execution through a pivotal year of integration, creating a unified biopharma entity with stronger global reach.
Read MorePress Release
News
Biosimilars
Key Milestones
View Full Legacy →Started in a garage in Bengaluru with a vision to make biopharmaceuticals affordable and accessible worldwide.
Biocon became the first Indian company to receive USFDA approval for a Lovastatin, marking a breakthrough in global compliance.
Biocon went public with India's largest biotech IPO at the time, listing on both the Bombay and National Stock Exchanges.
Launched India's first indigenously developed monoclonal antibody for head and neck cancer, a landmark in Indian biotech.
Biocon Biologics received landmark U.S. FDA approval for Trastuzumab biosimilar, making cancer treatment more affordable globally.
Semglee (Insulin Glargine) received historic U.S. FDA approval as the world's first-ever interchangeable biosimilar product.
A transformative acquisition that expanded Biocon Biologics into 120+ countries, becoming one of the world's top five biosimilar companies.
Successfully integrated the acquired business across 120 countries including North America, Europe, Japan, Australia and Emerging Markets.
Biocon Biologics surpassed the USD 1 billion revenue milestone, driven by robust growth across advanced and emerging markets.
Biocon completed the integration of its biosimilars and generics businesses, delivering 13% YoY revenue growth and 200bps EBITDA expansion.
Expanding access to life-saving biologic medicines globally
Affordable generic formulations and complex APIs
Addressing unmet medical needs with breakthrough science
Accelerating drug innovation and development worldwide
Trusted therapies across key therapeutic areas
Building the next generation of biopharma talent
WHO WE ARE
We are a global biopharmaceutical company with the belief that everyone, everywhere deserves access to affordable quality medicines. From biosimilars that democratize biologic therapy to novel biologics addressing unmet needs, Biocon is transforming lives at scale — guided by innovation, scientific rigor, and a steadfast commitment to patients.
Global markets reached with affordable biosimilars
Professionals across the Biocon Group worldwide
In our pipeline across oncology, diabetes & immunology
Benefit from our biosimilars across the globe each year
At Biocon, Diversity, Equity, and Inclusion is not a programme — it is the foundation of how we build teams, pursue science, and create impact. We believe that diverse perspectives lead to better innovation, stronger decisions, and more relevant outcomes for the patients we serve. We foster a collaborative environment where curiosity is rewarded, ownership is expected, and every team member is empowered to make a real difference in global healthcare.
Tell us what you need — whether you are a patient, partner, investor, or talent. We will connect you to the right team at Biocon.